<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1199">
  <stage>Registered</stage>
  <submitdate>12/06/2006</submitdate>
  <approvaldate>12/06/2006</approvaldate>
  <nctid>NCT00336219</nctid>
  <trial_identification>
    <studytitle>Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)</studytitle>
    <scientifictitle>COMPETITION: Investigation of Clinical Endpoints for Treatment-induced Gastroesophageal Reflux Disease (GERD) Symptom Changes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BY1023/M3-343</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>GERD</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pantoprazole

Active Comparator: 1 - Pantoprazole 40 mg


Treatment: drugs: Pantoprazole
Symptom Assessment after treatment with Pantoprozole 40 mg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>symptom assessment as measured by ReQuest questionnaire and investigator.</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>symptom assessment on days 7, 14, and 28 as measured by ReQuest questionnaire and investigator</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>endoscopic healing after 28 days</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>health-related quality of life after 28 days</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>safety.</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Main 

          -  Written informed consent

          -  Outpatients

          -  History of GERD-related symptoms for at least 6 months prior to study inclusion

          -  Endoscopically confirmed erosive GERD or non-erosive GERD

        Main</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Acute peptic ulcer and/or ulcer complications

          -  PPIs during last 7 days prior to study start

          -  Systemic glucocorticoids or non-steroidal anti-inflammatory drugs including COX-2
             inhibitors during the last 28 days prior to study start; except regular intake of
             acetylsalicylic acid up to a daily dose of 163 mg/day

          -  Intake of PPIs in combination with antibiotics for eradication of H. pylori</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>628</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Altana Pharma/Nycomed - Bondi Junction</hospital>
    <hospital>Altana Pharma/Nycomed - Box Hill, Victoria</hospital>
    <hospital>Altana Pharma/Nycomed - New South Wales</hospital>
    <hospital>Altana Pharma/Nycomed - South Australia</hospital>
    <postcode>NSW 2022 - Bondi Junction</postcode>
    <postcode>3128 - Box Hill, Victoria</postcode>
    <postcode>2138 - New South Wales</postcode>
    <postcode>5000 - South Australia</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Feldbach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Stockerau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wiener Neustadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Amberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aschersleben</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freising</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Germersheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Grünstadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jülich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köthen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Künzing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Landsberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Langen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ludwigshafen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lüneburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mönchengladbach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Potsdam-Babelsberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Reinfeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Saarbrücken</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Györ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Hatvan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kistarcsa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szentes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Vác</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Takeda</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to compare investigator and patient-assessed gastroesophageal reflux
      disease symptoms in patients with erosive GERD or endoscopic-negative GERD (enGERD). An
      endoscopy will be performed at study start and study end. During the study, the patients will
      complete a patient-orientated, self-assessed reflux questionnaire (ReQuest questionnaire).
      The study duration consists of a baseline period (8 days) and treatment period (28 days).
      Pantoprazole (tablet) will be administered once daily at one dose level. The study will
      provide further data on safety and tolerability of pantoprazole.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00336219</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gerald Holtmann, Prof.</name>
      <address>Department of Gastroenterology, Hepatology and General Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>